Combination therapy of apremilast and secukinumab in patients with moderate‐to‐severe, recalcitrant plaque psoriasis

Sacchelli, Lidia; Patrizi, Annalisa; Loi, Camilla; Bardazzi, Federico

doi:10.1111/ced.14000

Cited by 13 publications

(16 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only a few reports have described combination therapy with apremilast and biologics in patients with psoriasis . The proportions of patients who achieved PASI‐75 were higher in the previous reports than in our cases.…”

Section: Discussioncontrasting

confidence: 71%

“…Only a few reports have described combination therapy with apremilast and biologics in patients with psoriasis. [13][14][15] The proportions of patients who achieved PASI-75 were higher in the previous reports than in our cases. Although the reason for these differences in efficacy is unclear, it should be reiterated that the combination therapy with apremilast and biologic in this study was performed in patients with biologic fatigue.…”

Section: Discussioncontrasting

confidence: 65%

See 1 more Smart Citation

Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue

Takamura

Sugai

Taguchi

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Biologics have been shown to constitute a highly effective treatment for patients with psoriasis. However, a significant number of patients treated with biologics will discontinue them due to loss of efficacy over time, a phenomenon known as biologic fatigue or secondary failure. Combination therapy of biologics with other agents can be considered as a treatment option in such cases. Information regarding the efficacy and safety of adding apremilast to biologic therapy in patients with psoriasis is limited. In the present study, we retrospectively evaluated the efficacy and safety of apremilast combined with biologics in 14 patients with psoriasis showing biologic fatigue at a single hospital. Before the addition of apremilast, the mean Psoriasis Area and Severity Index (PASI) score was 3.2 ± 0.4. At week 24 following the addition of apremilast, the mean PASI score decreased to 1.6 ± 0.3, and four (29%) and seven (50%) patients had achieved 75% and 50% reduction in PASI score, respectively. During the 24 weeks of treatment, diarrhea was observed in four patients, and diarrhea and nausea were observed in one patient. Weight loss of more than 5% bodyweight was observed in two patients. None of the patients discontinued therapy because of these side‐effects. These results suggest that the combination therapy of apremilast and biologics could be a safe, effective option for the management of patients with psoriasis showing biologic fatigue.

show abstract

Section: Discussioncontrasting

confidence: 71%

Section: Discussioncontrasting

confidence: 65%

Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue

Takamura

Sugai

Taguchi

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Combination therapy has recently grown as a novel approach to provide better disease control for up to 30% of patients suffering recalcitrant psoriasis 7,8 . Our present case aligns with the success and safety of other combination therapy cases that included apremilast 2,7,8 .…”

Section: Figuresupporting

confidence: 80%

“…We present here the case of a 28-year-old Caucasian female patient with severe chronic plaque psoriasis that proved to be unre- Combination therapy has recently grown as a novel approach to provide better disease control for up to 30% of patients suffering recalcitrant psoriasis. 7,8 Our present case aligns with the success and safety F I G U R E 1 Clinical presentation prior to combined treatment. Multidrug-resistant psoriatic patient showed no response to anti-TNFα and anti-IL monotherapy treatments.…”

supporting

confidence: 80%

“…All pictures are published with patient's informed consent of other combination therapy cases that included apremilast. 2,7,8 Well tolerated, with mild AEs, and lower risk of immunosuppression and infections, 1,2 apremilast seems to improve efficacy when used in combination with other agents. Moreover, daily practice results in real-world settings have further reinforce the safety and efficacy of apremilast on psoriasis patients, including those infected with COVID-19.…”

mentioning

confidence: 99%

See 1 more Smart Citation